Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a fixed-dose combination drug containing orphenadrine, acetaminophen, caffeine, and diclofenac sodium. The formulation is designed to provide synergistic effects for the management of acute musculoskeletal pain and inflammation. - **Orphenadrine** is a centrally acting muscle relaxant with anticholinergic properties that helps relieve muscle spasm and associated pain. - **Acetaminophen** (paracetamol) acts as an analgesic and antipyretic by inhibiting prostaglandin synthesis in the central nervous system. - **Caffeine** serves as a central nervous system stimulant and can enhance the analgesic effect of other components. - **Diclofenac sodium** is a nonsteroidal anti-inflammatory drug (NSAID) that provides anti-inflammatory, analgesic, and antipyretic effects primarily through inhibition of cyclooxygenase enzymes COX-1 and COX-2[5]. The primary indication for this combination is the treatment of acute painful musculoskeletal conditions such as postural low back pain[5]. The rationale behind combining these agents is to achieve comprehensive relief by targeting different mechanisms involved in pain perception, inflammation, and muscle spasm.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on orphenadrine + acetaminophen + caffeine + diclofenac sodium.